Cargando…

Prevalence of Hyponatremia in Hypothyroid Patients during Radioactive (131)I Ablation for Differentiated Thyroid Cancer: Single Institution Experience

BACKGROUND: Hyponatremia developing in hypothyroid patients has been encountered in clinical practice; however, its prevalence has not been well established. METHODS: Thirty patients diagnosed with differentiated thyroid cancer, rendered hypothyroid after surgery and levothyroxine withdrawal, and wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dayrit, Juan Carlo P., Cunanan, Elaine C., Kho, Sjoberg A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053053/ https://www.ncbi.nlm.nih.gov/pubmed/27546873 http://dx.doi.org/10.3803/EnM.2016.31.3.410

Ejemplares similares

Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer
por: Iwano, Shingo, et al.
Publicado: (2020)

Analysis of the incidence and influencing factors of hyponatremia before (131)I treatment of differentiated thyroid carcinoma
por: Cao, Jing-Jia, et al.
Publicado: (2021)

Erratum to: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience
por: AL-Qahtani, Khalid Hussain, et al.
Publicado: (2016)

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131
por: PICIU, DOINA, et al.
Publicado: (2016)

DIFFERENTIATED THYROID CANCER IN PEDIATRIC POPULATION (≤18 YEARS): POSTOPERATIVE TREATMENT WITH RADIOACTIVE IODINE (I-131)
por: Prpić, Marin, et al.
Publicado: (2019)

RF16 | PSUN234 The Effect of Telemedicine on the Self-Care Activities of Patients with Type 2 Diabetes Mellitus and Patient Satisfaction during the COVID-19 Pandemic at the University of Santo Tomas Hospital
por: Bawal, Dionise Ysabelle, et al.
Publicado: (2022)

Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with (131)I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation
por: Signore, Alberto, et al.
Publicado: (2022)

Rate of thyroglossal duct remnant visualization after total thyroidectomy for differentiated thyroid carcinoma and its impact on clinical outcome of radioactive iodine (I-131) ablation
por: Mohamed Sayed, Mohamed Hosny, et al.
Publicado: (2015)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma
por: van der Boom, Trynke, et al.
Publicado: (2021)

Radioactive Body Burden Measurements in (131)Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body (131)Iodine Clearance
por: Ravichandran, Ramamoorthy, et al.
Publicado: (2014)

Estimation of effective half life of clearance of radioactive Iodine ((131)I) in patients treated for hyperthyroidism and carcinoma thyroid
por: Ravichandran, R, et al.
Publicado: (2010)

(131)I thyroid activity and committed dose assessment among family members of patients treated with radioactive iodine
por: Brudecki, K., et al.
Publicado: (2020)

Outcomes of Radioactive Iodine ((131)I) Therapy among Hyperthyroid patients
por: Khan, Muhammad Sajjad Ali, et al.
Publicado: (2023)

Risk Factors for Developing Hyponatremia in Thyroid Cancer Patients Undergoing Radioactive Iodine Therapy
por: Lee, Jung Eun, et al.
Publicado: (2014)

Prevalence of hypothyroidism in patients with hyponatremia: A retrospective cross-sectional study
por: Nagata, Takanobu, et al.
Publicado: (2018)

Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer
por: Lee, Chang-Hee, et al.
Publicado: (2018)

Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients
por: Kim, Jahae, et al.
Publicado: (2017)

The Nature and Rates of Excretion of Radioactive Breakdown Products of I(131)-Albumin in the Rabbit
por: Zizza, F., et al.
Publicado: (1959)

I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer
por: Lin, Rong, et al.
Publicado: (2015)

Hyponatremia due to Severe Primary Hypothyroidism in an Infant
por: Agathis, Nickolas T., et al.
Publicado: (2015)

Hypothyroidism Induced Hyponatremia: A Case Report
por: Maharjan, Gyabina, et al.
Publicado: (2022)

Is there a causal relationship between hypothyroidism and hyponatremia?
por: Chen, Julie
Publicado: (2023)

Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases
por: Al-Qahtani, Khalid Hussain, et al.
Publicado: (2014)

Recurrence-free survival and prognosis after adjuvant therapy with radioactive iodine-131 in patients with differentiated thyroid carcinoma
por: Iizuka, Yusuke, et al.
Publicado: (2023)

I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence
por: Shengguang, Yan, et al.
Publicado: (2016)

A PROGRESSIVE REACTION OCCURRING WITH A RADIOACTIVE HEMOLYSIN, SODIUM OLEATE-I(131)
por: Ponder, Eric, et al.
Publicado: (1958)

Transient cytotoxicity of (131)I beta radiation in hyperthyroid patients treated with radioactive iodine
por: Sundaram, P. Shanmuga, et al.
Publicado: (2011)

Predictive factors for the outcomes of Graves’ disease patients with radioactive iodine ((131)I) treatment
por: Xing, Yu-Zhuo, et al.
Publicado: (2020)

Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting
por: Ravichandran, Ramamoorthy, et al.
Publicado: (2016)

Is radioactive iodine- ( 131 ) treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
por: de Souza, Marcelo Cruzick, et al.
Publicado: (2015)

The Effects of the Factors Related to the Patient and the Disease on the Performance of Ablation Therapy in Patients with Differentiated Thyroid Cancer who have Received I-131 Ablation Therapy
por: Şengöz, Tarık, et al.
Publicado: (2012)

An indirect high iodine ((131)I) effective dose used for thyroid ablation in patients with thyroid cancer. Is the method of measurement important?
por: Al‐Shakhrah, Issa A.
Publicado: (2020)

TSH ≥30 mU/L may not be necessary for successful (131)I remnant ablation in patients with differentiated thyroid cancer
por: Ju, Nianting, et al.
Publicado: (2023)

Unexpected Uptake by the Gallbladder in Post-Ablative I-131 Scan
por: Ünal, Kemal, et al.
Publicado: (2015)

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
por: Probst, Stephan, et al.
Publicado: (2018)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

Use of Cesium-131 radioactive seeds in prostate permanent implants
por: Kehwar, T. S.
Publicado: (2009)

Therapeutic applications of radioactive (131)iodine: Procedures and incidents with capsules
por: Al Aamri, Marwa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lkkb0f9b4iotpp9lrke4mjj6j7